FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:420 January 26, 2006 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Pinero et al. (Nov. 3 issue)¹ describe a 74-year-old man with Parkinson's disease in whom severe mitral regurgitation developed after a relatively short course of treatment with cabergoline, an ergot dopamine agonist. Cabergoline is used in different settings at different doses. In patients with Parkinson's disease, the usual daily dose ranges from 2 to 6 mg,² whereas in hyperprolactinemia, the weekly dose ranges from 0.25 to 3.5 mg.³ So far, fibrotic reactions and valvular heart disease due to the use of ergot dopamine agonists have been reported almost exclusively in patients with Parkinson's disease and thus could . . . [Full Text of this Article]

Related Letters:

Cabergoline-Related Severe Restrictive Mitral Regurgitation
Pinero A., Marcos-Alberca P., Fortes J.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1976-1977, Nov 3, 2005. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.